Prostate Cancer - Results from #1200

Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. March 22, 2024

Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. March 22, 2024

[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617. March 22, 2024

Prostate cancer risk stratification via eNose urine odor analysis: a preliminary report. March 22, 2024

Expect the unexpected: investigating discordant prostate MRI and biopsy results. March 21, 2024

PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4-10 ng/ml. March 21, 2024

VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach. March 21, 2024

Topline/Final Diagnostic Inclusion of Relevant Histologic Findings in Surgical Pathology Reporting of Carcinoma in Prostate Biopsies. March 21, 2024

Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review. March 21, 2024

Surgical approach affecting long-term urinary continence status after robot-assisted laparoscopic prostatectomy prospectively evaluated using self-reported functional status (Expanded Prostate Cancer Index Composite, EPIC-26). March 21, 2024

Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes. March 21, 2024

Differences in Gut Microbiota Profiles and Microbiota Steroid Hormone Biosynthesis in Men with and Without Prostate Cancer. March 20, 2024

Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems. March 20, 2024

Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial. March 20, 2024

Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE". March 20, 2024

Performance of a Region of Interest-based Algorithm in Diagnosing International Society of Urological Pathology Grade Group ≥2 Prostate Cancer on the MRI-FIRST Database-CAD-FIRST Study. March 20, 2024

Using joint models for longitudinal and time-to-event data to investigate the causal effect of salvage therapy after prostatectomy. March 20, 2024

A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer. March 19, 2024

Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol. March 19, 2024

Exploring the relation of active surveillance schedules and prostate cancer mortality. March 19, 2024

Page 61 of 1436